

WEBINAR: What
can Europe learn
from Germany's
'National Decade
Against Cancer'?





17 June 2020, 11.00-12.00

CET



How is your connection? Ask a question?

If you are having problems with your connection, you can switch between phone and computer audio



We appreciate audience questions, please use the question bar in the control panel

Speakers:



Carsten Bokemeyer
Director
University Cancer Center Hamburg
(UCCH)




Antonella Cardone
Director
European Cancer Patient Coalition
(ECPC)



Olaf Ortmann
President
German Cancer Society



Deepak Khanna
Regional President Oncology for
EMEA and Canada
MSD



Duane Schulthess
Managing Director
Vital Transformation
(moderator)

Cancer Facts Germany

Olaf Ortmann
President
German Cancer Society

- Cancer is the second most common cause of death
- Number of new cases has doubled since 1970 and will increase from around 500 000 in 2020 to > 600 000 in 2030 (with aging population)
- 165 00 cases each year can be avoided by modifying life style factors
- Prevention: Colon cancer screening has prevented 180 000 new cancers cases in the last 10 years
- Dramatically prolonged life expectancy for patients with incurable cancers resulting from multimodal treatment, immunotherapies and personalized genomic-based cancer therapies



National Decade against Cancer

Motivation and Mission

- Cancer is a general population health problem
- Prevention, early diagnosis, therapy and aftercare need to be in the focus of intensive research leading to rapidly applicable results
- In addition to the **National Cancer Plan** (Nationaler Krebsplan), which targets on improving care, the **National Decade against Cancer** (2019-2028) will strategically complement this activity with a strong research focus and particular emphasis on clinical trials and translational research
- Multi-partner strategy involving politicians, cancer researchers, research funding organisations, health insurances, health-industry partners and the general society especially cancer patients

National Decade Against Cancer

Establishment of three working groups:

- Unresolved questions in cancer research
- Cancer prevention
- Generate knowledge by networking cancer research with cancer care.

Prof. Bokemeyer

Discussion working groups

Three working groups

- 1. Important questions in cancer research**
identify research questions of importance and define potential approach based on national research expertise
- 2. Prevention**
cancer incidence can be reduced by 40 % if prevention strategies are consequently and widely used
- 3. Knowledge generation by networking between research and routine care**
translation of innovative strategies into clinical care (antegrade translation)
derive research questions from clinical care data (retrograde translation)

Working Group:

Knowledge generation by connecting research and clinical care


- Early translation (from bench to innovative trials)
- Late translation (from clinical trials into routine care)
- Biomarkers and outcome parameters as important endpoints
- Treatment of patients in Oncology centers of excellence (DKH funded) and certified oncology community centers / networks
- Improve interaction and data exchange among academic and community-based qualified cancer care providers
- Analyse data from innovative national strategies (BRCA-network, nNGM lung cancer, DKG-documentation systems, and others)
- Integrate care and research data from psychosocial measures and palliative care

Several Aspects of funding

- Innovative cancer research
- Translational structures
(new NCT partner network with up to six centres)
- Practice changing clinical trials
- National institute of cancer prevention
- *Strategies for outcomes research, patient participation, data analysis and cohort studiesand more to come*


Q&A

Antonella Cardone: Germany aims to cure or control cancer long-term in 75% of patients by 2030, extending and saving lives. What are the challenges currently faced by cancer survivors and what does ECPC do to support them?




Q&A

Deepak Khanna; Given the economic challenges of COVID-19, are you at all concerned about the impact on national budgets to fund new, innovative treatments, for example, in combo-therapies which were already proving challenging before the pandemic?




Q&A

What is the perspective of ECPC on the impact of COVID-19 on the funding of cancer treatments and what changes to healthcare systems are needed to ensure patients receive the required cancer treatment and care?




Q&A

Germany's Decade Against Cancer comprehensively addresses R&D, testing, treatment, and new approaches to data management. Given most data systems are currently siloed within institutions, what fundamental changes to data systems needs to occur? What is the working group's position on data sharing with industry for R&D?




Q&A

The increasing use of personalized therapies (the right treatment for the right patient at the right time) can reduce long-term costs from the value chain, but not all healthcare systems value these benefits. This is creating unequal access to treatments in the EU. What can be done to fix the problem of unequal access across the EU member states?




Q&A

What role should Europe play in Germany's objectives related to cancer? What is Europe's vs. the Member States' role in defining cancer policy?




Q&A

Again, looking at the scope and breadth of changes in the Decade Against Cancer, how do we ensure that patients have a voice in cancer care? Does a commitment to improved cancer literacy support this end?



Q&A

Prof Bokemeyer, you lead one of Germany's Oncology Centre's of Excellence. What role will these centres play in translating new findings throughout the cancer infrastructure under the German Decade Against Cancer?



Audience Questions



Carsten Bokemeyer
Director
University Cancer Center Hamburg
(UCCH)




Antonella Cardone
Director
European Cancer Patient Coalition
(ECPC)




Olaf Ortmann
President
German Cancer Society



Deepak Khanna
Regional President Oncology for
EMEA and Canada
MSD




Duane Schulthess
Managing Director
Vital Transformation
(moderator)



Final Question:

The Decade Against Cancer has many steps and objectives; if you could, which one deliverable do you believe should be addressed not just in Germany, but also in other member states and Europe's Beating Cancer Plan to best improve outcomes for patients?



ISSUES IN CANCER CARE

The early bird debate series

	<p>NEXT WEBINAR</p> <p>Head & Neck The Cancer You Can See</p> <p>Chris Curtis: Swallows Head & Neck Cancer Support Group</p> <p>Susana Solis: Member of the European Parliament (MEP)</p>	
 MSD INVENTING FOR LIFE	July 8th 8:30am	 Brought to you by:  VitalTransformation

Register: bettersciencebetterhealth.com

Speakers:



Carsten Bokemeyer
Director
University Cancer Center Hamburg
(UCCH)




Antonella Cardone
Director
European Cancer Patient Coalition
(ECPC)



Olaf Ortmann
President
German Cancer Society



Deepak Khanna
Regional President Oncology for
EMEA and Canada
MSD



Duane Schulthess
Managing Director
Vital Transformation
(moderator)

WEBINAR: What
can Europe learn
from Germany's
'National Decade
Against Cancer'?

17 June 2020, 11.00-12.00

CET

